IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 19.1% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,342,415 shares of the medical research company's stock after selling 317,469 shares during the quarter. IQVIA makes up about 1.2% of Impax Asset Management Group plc's investment portfolio, making the stock its 25th largest holding. Impax Asset Management Group plc owned about 0.74% of IQVIA worth $309,957,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. HighTower Advisors LLC increased its holdings in shares of IQVIA by 2.4% during the first quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company's stock valued at $1,168,000 after purchasing an additional 118 shares during the period. Prudential PLC acquired a new position in shares of IQVIA during the first quarter valued at $741,000. Baird Financial Group Inc. increased its holdings in shares of IQVIA by 2.3% during the first quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company's stock valued at $23,021,000 after purchasing an additional 2,201 shares during the period. Parkside Financial Bank & Trust increased its holdings in shares of IQVIA by 59.0% during the first quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company's stock valued at $90,000 after purchasing an additional 144 shares during the period. Finally, Covestor Ltd grew its holdings in IQVIA by 82.2% during the first quarter. Covestor Ltd now owns 554 shares of the medical research company's stock worth $128,000 after acquiring an additional 250 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,000 shares of the company's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Eric Sherbet sold 1,000 shares of the company's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the company's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares of the company's stock, valued at $199,610,278.56. The disclosure for this sale can be found here. Insiders sold a total of 41,285 shares of company stock worth $10,331,003 over the last three months. 1.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on IQV shares. Robert W. Baird boosted their price target on shares of IQVIA from $226.00 to $251.00 and gave the stock a "neutral" rating in a research report on Thursday, February 15th. StockNews.com upgraded shares of IQVIA from a "hold" rating to a "buy" rating in a research report on Friday, February 16th. Evercore ISI boosted their price target on shares of IQVIA from $255.00 to $265.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 15th. Truist Financial boosted their price target on shares of IQVIA from $286.00 to $297.00 and gave the stock a "buy" rating in a research report on Tuesday, February 27th. Finally, UBS Group boosted their price target on shares of IQVIA from $240.00 to $300.00 and gave the stock a "buy" rating in a research report on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $256.80.

IQVIA Stock Up 1.6 %

NYSE:IQV traded up $3.83 on Tuesday, hitting $245.33. 546,067 shares of the company's stock traded hands, compared to its average volume of 995,440. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The firm has a 50-day moving average price of $241.84 and a 200-day moving average price of $220.12. The company has a market cap of $44.53 billion, a PE ratio of 33.65, a price-to-earnings-growth ratio of 2.34 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.02. The company had revenue of $3.87 billion for the quarter, compared to analysts' expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The business's revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.54 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.